effect overlay
activetrials

A Multicentre, Randomised, Double-Blind, Placebo Controlled Trial to Evaluate the Effectiveness and Safety of Sailuotong (SLT), a Standardised Herbal Medicine Formula in Patients with Vascular Dementia and Alzheimer's Disease with Cerebrovascular Disease
 

HREC: 2018.225
Principal Investigator: A/Prof Nawaf Yassi
Coordinator contact: Sophie Robinson
Funding: Non-Commercial
Dementia

Phase 3b open-label, multicenter, safety study of BIIB037 (aducanumab) in subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205
 

HREC: 2020.071
Principal Investigator: A/Prof David Darby
Coordinator contact: Lauren Martell
Funding: Commercial

A Phase 2b Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probably Behavioural Variant Fronto-temporal Dementia
 

HREC: 2020.171
Principal Investigator: Prof Dennis Velakoulis
Coordinator contact: Lauren Martell
Funding: Non-Commercial

Open Label Extension Study for Patients with Early Alzheimer’s Disease (AD) Enrolled in Study ANAVEX2-73-AD-004
 

HREC: 2020.257
Principal Investigator: Prof Amy Brodtmann
Coordinator contact: Sophie Robinson
Funding: Commercial
Dementia

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficiency and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease
 

HREC: 2020.271
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lesley-Anne Attard
Funding: Commercial